Background The life expectancy of people with HIV taking antiretroviral therapy (ART) has
increased substantially over the past 25 years. Most previous studies of life expectancy were …

Background Broad direct-acting antiviral (DAA) access may reduce hepatitis C virus (HCV)
incidence through a" treatment as prevention"(TasP) effect. We assessed changes in …

Conclusions: Non-liver non-AIDS–related events were the leading causes of morbidity and
mortality after direct-acting antiviral cure among coinfected patients with advanced …

Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and
causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly …

Background People who use drugs (PWUD) are a key target population to reduce the
burden of hepatitis C virus (HCV) infection. Aim To assess risk factors and temporal trends of …

Background Underlying immunodeficiency is associated with severe COVID-19, but the
prognosis of persons with human immunodeficiency virus (HIV)(PWH) with COVID-19 is …

Background Individuals with HIV and hepatitis C virus (HCV) who remain untreated with
direct-acting antivirals can contribute to HCV transmission and HCV-related mortality. We …

Abstract Background Once HIV/HCV-coinfection microelimination has been virtually
achieved in some countries, there is no information about the burden of liver disease among …

Abstract The Spanish Society of Digestive Pathology (SEPD), the Spanish Association for
the Study of the Liver (AEEH), the Spanish Society of Infections and Clinical Microbiology …

The complex epidemiology of hepatitis C virus (HCV) infection among human
immunodeficiency virus (HIV) patients in West Mexico remains poorly understood. Thus, this …